XLO
Xilio Therapeutics Inc

1,687
Mkt Cap
$39.53M
Volume
198,839.00
52W High
$1.70
52W Low
$0.615
PE Ratio
-1.14
XLO Fundamentals
Price
$0.7523
Prev Close
$0.753
Open
$0.753
50D MA
$0.7867
Beta
0.72
Avg. Volume
580,505.22
EPS (Annual)
-$1.09
P/B
-4.82
Rev/Employee
$99,125.00
Loading...
Loading...
News
all
press releases
Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates
Xilio Therapeutics (XLO) delivered earnings and revenue surprises of 0.00% and -28.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
More News
News Placeholder
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -41.56% and -34.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·13d ago
News Placeholder
Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued
The company has begun dosing patients in Phase 2 of its trial for XTX301, a tumor-activated IL-12 therapy that showed two partial responses in early testing and was generally well tolerated.
Stocktwits·3mo ago
News Placeholder
Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates
Xilio Therapeutics (XLO) delivered earnings and revenue surprises of -100.00% and -10.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
TD Cowen Remains a Buy on Xilio Therapeutics (XLO)
TD Cowen analyst Marc Frahm maintained a Buy rating on Xilio Therapeutics (XLO Research Report) yesterday. The company's shares closed yesterday...
TipRanks Financial Blog·1y ago
News Placeholder
Xilio Therapeutics reports Q4 results
Xilio Therapeutics reports Q4 results...
SeekingAlpha.com: All News·2y ago
News Placeholder
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS...
Globe Newswire·2y ago
News Placeholder
12 titoli sanitari in movimento, sessione regolare del 01/04/2024
Titoli in rialzo Le azioni di Sunshine Biopharma (NASDAQ:SBFM) hanno fatto segnare +84,29% a 0,11 dollari durante la sessione regolare di luned . Le azioni di Xilio Therapeutics (NASDAQ:XLO) sono...
Benzinga·2y ago
News Placeholder
12 acciones de salud en movimiento en la sesi n intrad a del 01/04/2024
Acciones al alza Sunshine Biopharma (NASDAQ:SBFM) se anotaron un alza del 93,22% para establecerse en los 0,12 d lares durante la sesi n del regular del lunes. Xilio Therapeutics (NASDAQ:XLO) ganaron...
Benzinga·2y ago
News Placeholder
12 titres de soins de sant en mouvement lors de la pr -ouverture le 29/03/2024
Gagnants Le titre Avalo Therapeutics (NASDAQ:AVTX) a mont vendredi de 289,05% 18,48 dollars lors de la session pre-market. Le titre Xilio Therapeutics (NASDAQ:XLO) a grimp de 205,16% 1,95...
Benzinga·2y ago

Latest XLO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.